As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare providers & services industry, including The Ensign Group (NASDAQ:ENSG) and its peers.

A months-long battle over rates between North Kansas City Health and Blue Cross and Blue Shield of Kansas City (Blue KC) is ...

CardiAMP Cell Therapy for ischemic heart failure holds FDA breakthrough status and is reimbursed at $20,000 per procedure in ...

Evidence is emerging that Australia is being reconsidered as a destination for the launch of a host of new drugs by ...

The global left atrial appendage closure (LAAC) devices market is expected to witness substantial growth and is projected to expand at a CAGR of nearly 15% over the next five years. The increasing ...

The theme for the annual budget debate this year in the Senate is sunflowers because of the plant’s ability to withstand ...

While 2025 saw significant federal and state legislative changes, the health care landscape in North and South Carolina continues to evolve in ...

Carolina Carrasco, senior director at IQVIA, explores how fragmented financial workflows can create administrative burden and ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a novel, FDA-cleared ...

Find the best health insurance in the Netherlands for 2026. Compare CZ, Zilveren Kruis, VGZ, Menzis & DSW — premiums explained.